Proteus Syndrome Foundation

      Donate       

Patient Registry 

Connect WIth Us

  • PSF Home
  • About Us
    • Who We Are
    • Mission Statement
    • Board of Directors
    • Medical Advisory Board
    • Partners
  • Patients & Families
    • About Proteus Syndrome
    • Clinical Trials
    • Genetic Testing
    • Resources
      • Videos
      • Documentary
      • Glossary
  • Researchers & Physicians
    • Proteus 101
    • Clinical Trials & Research Pipeline
    • Genetic Testing
    • Resources
  • Ways to Help
    • Donate
    • Fundraise
    • Family Assistance Program
    • The Jackie Johnson Sparkle Grant
  • Contact Us
  • Subscribe
  • PSF Home
  • About Us
    • Who We Are
    • Mission Statement
    • Board of Directors
    • Medical Advisory Board
    • Partners
  • Patients & Families
    • About Proteus Syndrome
    • Clinical Trials
    • Genetic Testing
    • Resources
      • Videos
      • Documentary
      • Glossary
  • Researchers & Physicians
    • Proteus 101
    • Clinical Trials & Research Pipeline
    • Genetic Testing
    • Resources
  • Ways to Help
    • Donate
    • Fundraise
    • Family Assistance Program
    • The Jackie Johnson Sparkle Grant
  • Contact Us
  • Subscribe

Clinical Trials & Research Pipeline

Picture
The Phase 1/2 MOSAIC trial (NCT03094832) is currently the only ongoing interventional clinical trial for the treatment of Proteus syndrome. Massachusetts-based biotechnology company ArQule has designed the MOSAIC trial to determine whether its small molecule AKT inhibitor, miransertib, can effectively treat individuals with Proteus syndrome and other overgrowth spectrum disorders. To be eligible for the trial, individuals must have a documented mutation in the AKT1 gene. 
 
Preclinical research has demonstrated that miransertib suppresses PIK3CA/AKT1 mutant dependent kinase signaling and demonstrates anti-tumor activity in molecularly defined tumor models. Preliminary clinical data suggests that miransertib improves disease-related symptoms and objective condition assessments.
Picture
AIMProteus
             AKT Inhibitor Miransertib on Proteus Syndrome  - Targeted therapy at NIH
Update:  The AIM Proteus Trial is currently in IRB review status.
Approximate patient enrollment date for trial - Late Feb-March 2020

The NIH team is very excited about the opening of this phase 2 clinical trial. They will be hosting an Educational Information Session Webinar on Tuesday, January 21st at 11:00am eastern standard time. concerning:
  • trial status 
  • the next steps for enrollment 
We will post a link for the webinar soon. 

Questions about the NIH AIMProteus trial email here or call. ​

Donate

Picture

Follow Us

Picture
The Proteus Syndrome Foundation, a 501c3 not-for-profit organization, is dedicated improving the lives of Proteus patients by funding AKT1 research. We focus on providing family support in the form of education and networking individuals living with Proteus syndrome with other families and medical professionals.

​Website Design by Timberline Webworks
Alex Hoag
In Loving Memory of
Alexander Hoag
7/5/90 - 9/20/99
"He did a lot in 9 short years."
Vertical Divider
  • PSF Home
  • About Us
    • Who We Are
    • Mission Statement
    • Board of Directors
    • Medical Advisory Board
    • Partners
  • Patients & Families
    • About Proteus Syndrome
    • Clinical Trials
    • Genetic Testing
    • Resources
      • Videos
      • Documentary
      • Glossary
  • Researchers & Physicians
    • Proteus 101
    • Clinical Trials & Research Pipeline
    • Genetic Testing
    • Resources
  • Ways to Help
    • Donate
    • Fundraise
    • Family Assistance Program
    • The Jackie Johnson Sparkle Grant
  • Contact Us
  • Subscribe